PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26945158-0 2016 Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents. Eicosapentaenoic Acid 0-21 apolipoprotein B Homo sapiens 44-48 29331380-1 2018 The omega-3 fatty acid eicosapentaenoic acid (EPA) reduces oxidation of ApoB-containing particles in vitro and in patients with hypertriglyceridemia. Eicosapentaenoic Acid 23-44 apolipoprotein B Homo sapiens 72-76 29331380-1 2018 The omega-3 fatty acid eicosapentaenoic acid (EPA) reduces oxidation of ApoB-containing particles in vitro and in patients with hypertriglyceridemia. Eicosapentaenoic Acid 46-49 apolipoprotein B Homo sapiens 72-76 26945158-1 2016 Eicosapentaenoic acid (EPA) is a triglyceride-lowering agent that reduces circulating levels of the apolipoprotein B (apoB)-containing lipoprotein particles small dense low-density lipoprotein (sdLDL), very-low-density lipoprotein (VLDL), and oxidized low-density lipoprotein (LDL). Eicosapentaenoic Acid 0-21 apolipoprotein B Homo sapiens 100-116 26945158-1 2016 Eicosapentaenoic acid (EPA) is a triglyceride-lowering agent that reduces circulating levels of the apolipoprotein B (apoB)-containing lipoprotein particles small dense low-density lipoprotein (sdLDL), very-low-density lipoprotein (VLDL), and oxidized low-density lipoprotein (LDL). Eicosapentaenoic Acid 0-21 apolipoprotein B Homo sapiens 118-122 26945158-1 2016 Eicosapentaenoic acid (EPA) is a triglyceride-lowering agent that reduces circulating levels of the apolipoprotein B (apoB)-containing lipoprotein particles small dense low-density lipoprotein (sdLDL), very-low-density lipoprotein (VLDL), and oxidized low-density lipoprotein (LDL). Eicosapentaenoic Acid 23-26 apolipoprotein B Homo sapiens 100-116 26945158-1 2016 Eicosapentaenoic acid (EPA) is a triglyceride-lowering agent that reduces circulating levels of the apolipoprotein B (apoB)-containing lipoprotein particles small dense low-density lipoprotein (sdLDL), very-low-density lipoprotein (VLDL), and oxidized low-density lipoprotein (LDL). Eicosapentaenoic Acid 23-26 apolipoprotein B Homo sapiens 118-122 26945158-10 2016 These data support recent clinical findings and suggest that EPA has direct antioxidant benefits in various apoB-containing subfractions that are more pronounced than those of other triglyceride-lowering agents and docosahexaenoic acid. Eicosapentaenoic Acid 61-64 apolipoprotein B Homo sapiens 108-112 27143943-9 2016 Available data on the effects of OM3FAs in patients with diabetes and/or metabolic syndrome support that these products can be used safely in patients with T2DM and have beneficial effects on atherogenic parameters; in particular, the EPA-only prescription product significantly reduced TG, non-high-density lipoprotein cholesterol, Apo B, remnant lipoprotein cholesterol, and high-sensitivity CRP levels without increasing LDL-C levels compared with placebo. Eicosapentaenoic Acid 235-238 apolipoprotein B Homo sapiens 333-338 26073395-11 2015 CONCLUSION: The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides. Eicosapentaenoic Acid 35-38 apolipoprotein B Homo sapiens 48-52 7772067-0 1995 Similar to oleic acid, eicosapentaenoic acid stimulates apolipoprotein B secretion by inhibiting its intracellular degradation in Hep G2 cells. Eicosapentaenoic Acid 23-44 apolipoprotein B Homo sapiens 56-72 16482073-9 2006 Intake of EPA/DHA also increased apoB concentrations by 14 mg/dl (P = 0.0031, 95% CI (4, 23 mg/dl)) and 12 mg/dl (P = 0.005, 95% CI (3, 21 mg/dl)) versus the oleic acid and ALA-rich diet, respectively. Eicosapentaenoic Acid 10-13 apolipoprotein B Homo sapiens 33-37 7742360-0 1995 Differential effects of eicosapentaenoic acid on glycerolipid and apolipoprotein B metabolism in primary human hepatocytes compared to HepG2 cells and primary rat hepatocytes. Eicosapentaenoic Acid 24-45 apolipoprotein B Homo sapiens 66-82 7742360-1 1995 We compared the effects of eicosapentaenoic acid (EPA) and oleic acid (OA) on glycerolipid and apolipoprotein B (apoB) metabolism in primary human hepatocytes, HepG2 cells and primary rat hepatocytes. Eicosapentaenoic Acid 50-53 apolipoprotein B Homo sapiens 113-117 7742360-10 1995 In contrast, both EPA and OA increased cellular and medium apoB abundance 2- to 2.5-fold in HepG2 cells, although medium apoB tended to be lower in EPA-treated cells. Eicosapentaenoic Acid 18-21 apolipoprotein B Homo sapiens 59-63 1332692-10 1992 These results demonstrate that EPA can be toxic to hepatocytes and that NEFAs and insulin control secretion of triacylglycerol and apo-B by regulation of the intracellular apo-B concentration, thus controlling assembly of apo-B with triacylglycerol to form lipoproteins. Eicosapentaenoic Acid 31-34 apolipoprotein B Homo sapiens 172-177 7945235-6 1994 The secretion of both labelled and total triacylglycerol and apolipoprotein B was reduced approximately 50% in cells incubated chronically with eicosapentaenoic acid. Eicosapentaenoic Acid 144-165 apolipoprotein B Homo sapiens 61-77 1332692-10 1992 These results demonstrate that EPA can be toxic to hepatocytes and that NEFAs and insulin control secretion of triacylglycerol and apo-B by regulation of the intracellular apo-B concentration, thus controlling assembly of apo-B with triacylglycerol to form lipoproteins. Eicosapentaenoic Acid 31-34 apolipoprotein B Homo sapiens 172-177 1402397-10 1992 Eicosapentaenoic acid and oleic acid are absorbed, metabolized, and influence secretion of lipoprotein particles in a similar way, except for some differences in incorporation of the fatty acids into certain phospholipid classes and a reduced secretion of apolipoprotein B. Eicosapentaenoic Acid 0-21 apolipoprotein B Homo sapiens 256-272 1591230-0 1992 Apolipoprotein B mRNA abundance is decreased by eicosapentaenoic acid in CaCo-2 cells. Eicosapentaenoic Acid 48-69 apolipoprotein B Homo sapiens 0-16 1591230-2 1992 The regulation of apolipoprotein B (apo B) metabolism by eicosapentaenoic acid was investigated in CaCo-2 cells. Eicosapentaenoic Acid 57-78 apolipoprotein B Homo sapiens 18-34 1591230-2 1992 The regulation of apolipoprotein B (apo B) metabolism by eicosapentaenoic acid was investigated in CaCo-2 cells. Eicosapentaenoic Acid 57-78 apolipoprotein B Homo sapiens 36-41 1591230-6 1992 The secretion of triglyceride and apo B mass by cells incubated with eicosapentaenoic acid was less than that observed by cells incubated with oleate. Eicosapentaenoic Acid 69-90 apolipoprotein B Homo sapiens 34-39 1591230-8 1992 Apo B mRNA abundance was decreased fourfold in cells exposed for 48 hours to eicosapentaenoic acid. Eicosapentaenoic Acid 77-98 apolipoprotein B Homo sapiens 0-5 1591230-11 1992 In cells incubated with eicosapentaenoic acid, the synthesis and basolateral secretion of newly synthesized apo B-100 and apo B-48 were significantly less compared with control cells or cells incubated with oleic acid. Eicosapentaenoic Acid 24-45 apolipoprotein B Homo sapiens 108-117 1591230-11 1992 In cells incubated with eicosapentaenoic acid, the synthesis and basolateral secretion of newly synthesized apo B-100 and apo B-48 were significantly less compared with control cells or cells incubated with oleic acid. Eicosapentaenoic Acid 24-45 apolipoprotein B Homo sapiens 108-113 1591230-14 1992 Compared with control cells and cells incubated with eicosapentaenoic acid, the residence time of labeled apo B in cells incubated with oleic acid was prolonged. Eicosapentaenoic Acid 53-74 apolipoprotein B Homo sapiens 106-111 1591230-17 1992 Thus, in CaCo-2 cells, compared with the effects of oleic acid, eicosapentaenoic acid impairs triglyceride transport in part by inhibiting apo B synthesis and secretion. Eicosapentaenoic Acid 64-85 apolipoprotein B Homo sapiens 139-144 1591230-18 1992 The inhibition of apo B synthesis by eicosapentaenoic acid may be related to a decrease in gene transcription or a decrease in mRNA stability, as apo B mRNA levels were significantly decreased in cells incubated with this fatty acid. Eicosapentaenoic Acid 37-58 apolipoprotein B Homo sapiens 18-23 1591230-18 1992 The inhibition of apo B synthesis by eicosapentaenoic acid may be related to a decrease in gene transcription or a decrease in mRNA stability, as apo B mRNA levels were significantly decreased in cells incubated with this fatty acid. Eicosapentaenoic Acid 37-58 apolipoprotein B Homo sapiens 146-151 3035811-3 1987 Eicosapentaenoic acid (20:5, n-3) has a triglyceride- and cholesterol-reducing effect by inhibition of the VLDL-synthesis (apolipoprotein B, triglycerides) in the liver, inhibition of lipogenic liver enzymes, accelerated elimination of VLDL from the circulation, increased excretion of steroids and bile acids into the stools and amelioration of the fat tolerance. Eicosapentaenoic Acid 0-21 apolipoprotein B Homo sapiens 123-139